GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2

被引:100
作者
Biosa, Alice [1 ,2 ]
Trancikova, Alzbeta [1 ]
Civiero, Laura [3 ]
Glauser, Liliane [1 ]
Bubacco, Luigi [3 ]
Greggio, Elisa [3 ]
Moore, Darren J. [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Brain Mind Inst, Sch Life Sci, CH-1015 Lausanne, Switzerland
[2] Univ Sassari, Sch Med, Dept Clin & Expt Med, I-07100 Sassari, Italy
[3] Univ Padua, Dept Biol, I-35121 Padua, Italy
基金
瑞士国家科学基金会;
关键词
ROC DOMAIN; GENE LRRK2; PROTEIN; MUTATIONS; BINDING; PHOSPHORYLATION; REVEALS; DIMER;
D O I
10.1093/hmg/dds522
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in the LRRK2 gene cause autosomal dominant Parkinson's disease. LRRK2 encodes a multidomain protein containing a Ras-of-complex (Roc) GTPase domain, a C-terminal of Roc domain and a protein kinase domain. LRRK2 can function as a GTPase and protein kinase, although the interplay between these two enzymatic domains is poorly understood. Although guanine nucleotide binding is critically required for the kinase activity of LRRK2, the contribution of GTP hydrolysis is not known. In general, the molecular determinants regulating GTPase activity and how the GTPase domain contributes to the properties of LRRK2 remain to be clarified. Here, we identify a number of synthetic missense mutations in the GTPase domain that functionally modulate GTP binding and GTP hydrolysis and we employ these mutants to comprehensively explore the contribution of GTPase activity to the kinase activity and cellular phenotypes of LRRK2. Our data demonstrate that guanine nucleotide binding and, to a lesser extent, GTP hydrolysis are required for maintaining normal kinase activity and both activities contribute to the GTP-dependent activation of LRRK2 kinase activity. Guanine nucleotide binding but not GTP hydrolysis regulates the dimerization, structure and stability of LRRK2. Furthermore, GTP hydrolysis regulates the LRRK2-dependent inhibition of neurite outgrowth in primary cortical neurons but is unable to robustly modulate the effects of the familial G2019S mutation. Our study elucidates the role of GTPase activity in regulating kinase activity and cellular phenotypes of LRRK2 and has important implications for the validation of the GTPase domain as a molecular target for attenuating LRRK2-mediated neurodegeneration.
引用
收藏
页码:1140 / 1156
页数:17
相关论文
共 50 条
  • [41] LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease
    Sosero, Yuri L.
    Yu, Eric
    Krohn, Lynne
    Rudakou, Uladzislau
    Mufti, Kheireddin
    Ruskey, Jennifer A.
    Asayesh, Farnaz
    Laurent, Sandra B.
    Spiegelman, Dan
    Fahn, Stanley
    Waters, Cheryl
    Sardi, S. Pablo
    Bandres-Ciga, Sara
    Alcalay, Roy N.
    Gan-Or, Ziv
    Senkevich, Konstantin
    NEUROBIOLOGY OF AGING, 2021, 103 : 142.e1 - 142.e5
  • [42] Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase
    Lis, Pawel
    Burel, Sophie
    Steger, Martin
    Mann, Matthias
    Brown, Fiona
    Diez, Federico
    Tonelli, Francesca
    Holton, Janice L.
    Ho, Philip Winglok
    Ho, Shu-Leong
    Chou, Meng-Yun
    Polinski, Nicole K.
    Martinez, Terina N.
    Davies, Paul
    Alessi, Dario R.
    BIOCHEMICAL JOURNAL, 2018, 475 : 1 - 22
  • [43] Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models
    Liu, Zhaohui
    Hamamichi, Shusei
    Lee, Byoung Dae
    Yang, Dejun
    Ray, Arpita
    Caldwell, Guy A.
    Caldwell, Kim A.
    Dawson, Ted M.
    Smith, Wanli W.
    Dawson, Valina L.
    HUMAN MOLECULAR GENETICS, 2011, 20 (20) : 3933 - 3942
  • [44] Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils
    Fan, Ying
    Howden, Andrew J. M.
    Sarhan, Adil R.
    Lis, Pawel
    Ito, Genta
    Martinez, Terina N.
    Brockmann, Kathrin
    Gasser, Thomas
    Alessi, Dario R.
    Sammler, Esther M.
    BIOCHEMICAL JOURNAL, 2018, 475 : 23 - 44
  • [45] Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures
    Sanz Murillo, Marta
    Villagran Suarez, Amalia
    Dederer, Verena
    Chatterjee, Deep
    Alegrio Louro, Jaime
    Knapp, Stefan
    Mathea, Sebastian
    Leschziner, Andres E.
    SCIENCE ADVANCES, 2023, 9 (48)
  • [46] Exploring the focal role of LRRK2 kinase in Parkinson's disease
    Kumar, Sachin
    Behl, Tapan
    Sehgal, Aayush
    Chigurupati, Sridevi
    Singh, Sukhbir
    Mani, Vasudevan
    Aldubayan, Maha
    Alhowail, Ahmed
    Kaur, Satvinder
    Bhatia, Saurabh
    Al-Harrasi, Ahmed
    Subramaniyan, Vetriselvan
    Fuloria, Shivkanya
    Fuloria, Neeraj Kumar
    Sekar, Mahendran
    Daim, Mohamed M. Abdel
    ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2022, 29 (22) : 32368 - 32382
  • [47] Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
    Nichols, R. Jeremy
    Dzamko, Nicolas
    Hutti, Jessica E.
    Cantley, Lewis C.
    Deak, Maria
    Moran, Jennifer
    Bamborough, Paul
    Reith, Alastair D.
    Alessi, Dario R.
    BIOCHEMICAL JOURNAL, 2009, 424 : 47 - 60
  • [48] The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro
    Gloeckner, Christian Johannes
    Schumacher, Annette
    Boldt, Karsten
    Ueffing, Marius
    JOURNAL OF NEUROCHEMISTRY, 2009, 109 (04) : 959 - 968
  • [49] The In Situ Structure of Parkinson's Disease-Linked LRRK2
    Watanabe, Reika
    Buschauer, Robert
    Bohning, Jan
    Audagnotto, Martina
    Lasker, Keren
    Lu, Tsan-Wen
    Boassa, Daniela
    Taylor, Susan
    Villa, Elizabeth
    CELL, 2020, 182 (06) : 1508 - +
  • [50] LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting
    Xiong, Yulan
    Yu, Jianzhong
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (10) : 982 - 996